Background & Aims Identifying patients at high risk of immunogenicity is important when
selecting tumor necrosis factor (TNF)-α antagonists in patients with immune-mediated …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

Background Immunogenicity to tumour necrosis factor inhibitors is a significant clinical
problem leading to treatment failure and adverse events. The study aimed to assess human …

Background Antidrug antibodies to TNF inhibitors might affect clinical outcomes. Proactive
therapeutic drug monitoring allows for early detection of antidrug antibodies and might …

Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …

The evolution of personalized medicine in dermatology signifies a transformative shift
towards individualized treatments, driven by the integration of biomarkers. These molecular …

Objectives To explore associations between serum adalimumab level, treatment response
and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of …

Objectives This article aims to evaluate the effect of the extended dosing interval on the
efficacy and safety of ozoralizumab in patients with rheumatoid arthritis (RA). Methods In a …

Tumor necrosis factor inhibitors (TNFi) have revolutionized the treatment of inflammatory
joint diseases, but a large proportion of patients either do not respond adequately to the …

We investigated associations of obesity and tobacco smoking with health-related quality of
life (HRQoL), pain, fatigue, and functional impairment in systemic lupus erythematosus …